Immunovant Inc IMVT 深 沪
已收盘 01-30 16:00:00 美东时间
26.00
-0.450
-1.70%
华盛通- 最 高26.42
- 今 开26.20
- 成交量 182.55万股
- 最 低 25.42
- 昨 收 26.45
- 总市值 44.46亿
- 52周最高 27.80
- 市盈率 静 --
- 换手率 1.07%
- 52周最低 12.72
- 委 比 -56.52%
- 总股本 1.71亿
- 历史最高 53.75
- 量 比 1.83
- 振 幅 3.78%
- 历史最低 3.145
- 每 手 1
- 风险率 3.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up
Insiders have been trading these 5 stocks: (($APLS)), (($OLMA)), (($XCUR)), (($...
01-24 21:01
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Immunovant will report its third-quarter 2025 financial results and provide a business update on February 6, 2026, at 8:00 a.m. ET. Interested parties can access the conference call via the provided registration link or under “News & Events” on Immunovant’s investor website. The webcast will be archived for later access. Immunovant, a clinical-stage immunology company, focuses on developing innovative therapies for autoimmune diseases using anti-...
01-23 22:25
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
Wolfe Research Upgrades Immunovant to Outperform, Announces $50 Price Target
Wolfe Research analyst Andy Chen upgrades Immunovant (NASDAQ:IMVT) from Peer Perform to Outperform and announces $50 price target.
01-06 21:22
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
Roivant Says Three New Drugs Could Hit the Market in the Next Three Years, Speeds Up Trial Timelines as It Prepares for Major Product Launches ,
Roivant (NASDAQ:ROIV) today is hosting an Investor Day in New York City. Roivant leadership will highlight key pipeline updates and provide an update on the Company's strategy for long-term value creation."We are at
2025-12-11 20:35
Immunovant drops 7%, prices $550M stock offering
Clinical-stage immunology company Immunovant (IMVT) priced an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of ~$550M. Roivant Sciences, the company’s contro...
2025-12-11 18:48
Immunovant Announces Pricing of $550 Million Common Stock Financing
Immunovant, a clinical-stage immunology company, announced the pricing of an underwritten offering of its common stock, expecting gross proceeds of approximately $550 million. The funds are intended to support its operations and capital expenditures through the potential commercial launch of IMVT-1402 for Graves' Disease. Immunovant is offering 26.2 million shares at $21.00 per share, with the offering expected to close on December 12, 2025. Leer...
2025-12-11 06:29
Immunovant shares are trading higher. The company reported Q2 EPS results.
Immunovant shares are trading higher. The company reported Q2 EPS results.
2025-11-10 22:09
